Financial Performance - The company's operating revenue for Q3 2023 reached ¥788,153,786.15, an increase of 45.13% compared to the same period last year[4] - Net profit attributable to shareholders was ¥82,416,270.88, reflecting a significant increase of 92.83% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥81,401,230.63, up 94.47% from the previous year[4] - Basic and diluted earnings per share were both ¥0.55, representing an increase of 89.66% year-on-year[4] - The company's operating revenue for the first nine months of 2023 reached ¥2,166,125,568.45, a year-on-year increase of 51.19% compared to ¥1,432,759,189.01 in the same period of 2022[24] - Total operating revenue for the third quarter reached ¥2,166,125,568.45, a 51.2% increase from ¥1,432,759,189.01 in the same period last year[42] - Net profit for the quarter was ¥325,742,470.01, compared to ¥94,004,084.92 in the previous year, representing a significant increase[43] - Earnings per share (EPS) for the quarter was ¥2.12, up from ¥0.75 in the same quarter last year[43] - The total comprehensive income for the quarter attributable to shareholders of the parent company was ¥317,242,547.43, compared to ¥94,004,084.92 in the previous year[43] Assets and Liabilities - The total assets of the company at the end of Q3 2023 amounted to ¥4,856,224,774.50, a growth of 32.07% compared to the end of the previous year[4] - The total assets increased to ¥4,856,224,774.50, compared to ¥3,676,965,643.95 in the previous year, reflecting a growth of 32.0%[38] - Total liabilities rose to ¥2,463,367,180.83, an increase from ¥1,609,443,357.54, marking a growth of 53.1%[38] - The equity attributable to shareholders increased to ¥2,369,802,929.04, up 14.62% from the end of the previous year[4] - The total equity attributable to shareholders of the parent company was ¥2,369,802,929.04, up from ¥2,067,522,286.41, indicating a growth of 14.6%[38] Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was ¥548,228,797.85, an increase of 108.62% year-on-year[15] - The company reported a significant increase in cash flow from operating activities due to expanding sales scale[15] - Operating cash flow for the current period was ¥548,228,797.85, a significant increase of 108.5% compared to ¥262,784,150.96 in the previous period[45] - Total cash inflow from operating activities reached ¥2,135,541,943.55, up from ¥1,436,491,234.49, reflecting a growth of 48.6%[45] - Cash outflow from operating activities was ¥1,587,313,145.70, compared to ¥1,173,707,083.53 in the previous period, marking an increase of 35.4%[45] Expenses - Operating costs increased to ¥1,179,555,373.73, reflecting a growth of 48.21% from ¥795,891,600.39 in the previous year, primarily due to the rise in revenue[24] - Total operating costs amounted to ¥1,846,235,666.59, up 40.8% from ¥1,310,235,862.48 year-over-year[42] - Research and development expenses surged by 64.22% to ¥7,155,122.27, up from ¥4,357,149.04, driven by increased spending on ophthalmology-related clinical applications and digital research[24] - Research and development expenses for the quarter were ¥7,155,122.27, compared to ¥4,357,149.04 in the previous year, reflecting a 64.3% increase[42] - Sales expenses rose by 30.12% to ¥346,451,019.62, up from ¥266,262,117.61, mainly due to higher salaries for sales personnel and increased advertising costs[24] - Management expenses increased by 29.56% to ¥262,937,736.30, compared to ¥202,941,256.77, largely due to higher salaries for management and depreciation from newly opened hospitals[24] - Financial expenses grew by 19.56% to ¥45,982,355.34, up from ¥38,458,390.59, primarily due to increased interest expenses from new lease agreements[24] - Other income increased by 46.85% to ¥12,360,128.11, compared to ¥8,416,920.22, mainly due to an increase in government subsidies recognized in the current period[24] Investments and Future Plans - The company has made investments in new technologies and market expansion, as indicated by the increase in fixed assets and goodwill[20] - The company plans to repurchase shares with a total amount not less than ¥50 million and not exceeding ¥60 million, with a repurchase price not exceeding ¥151.74 per share[19] - The company plans to continue expanding its market presence and investing in new technologies to enhance its service offerings[25] - The company plans to use repurchased shares for employee stock ownership plans or equity incentives in the future[54] Shareholder Information - The company has a strong shareholder base, with the top ten shareholders holding a significant portion of the shares, indicating robust investor confidence[28] - The total number of ordinary shareholders at the end of the reporting period was 5,351, with the largest shareholder holding 35.91%[52] Accounts and Inventory - Accounts receivable increased by 93.90% to $112,742,685.98 due to the growth in operating income[59] - Prepayments surged by 212.38% to $30,506,969.14 as a result of expanded business scale[59] - Inventory rose by 34.21% to $144,431,640.90, attributed to business growth[59] Fixed Assets and Investments - Fixed assets increased by 72.26% to $675,387,232.33 primarily from the acquisition of buildings[59] - Construction in progress grew by 126.84% to $141,786,374.59 due to increased renovation costs for new hospitals[59] - Right-of-use assets rose by 53.68% to $1,566,587,996.33 from new hospital lease agreements[59] - Intangible assets increased by 374.67% to $49,733,523.92 due to the acquisition of land use rights[59] - Goodwill surged by 1404.99% to $412,127,411.92 as a result of a merger with a previously associated company[59] - Long-term equity investments decreased by 60.57% to $105,435,559.03 due to a change in the status of an investee company[59] - Other non-current assets decreased by 96.17% to $11,822,485.90 due to the merger and reduction in prepayments[59]
普瑞眼科(301239) - 2023 Q3 - 季度财报